All In Biotech

Drug Trial Radar · NCT07158775

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAGChronosFP) in Patients With Geographic Atrophy Secondary to Dry AMD

Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jan 8, 2026

Primary completion

Dec 2027

Study completion Dec 2031

Sponsor

Lead sponsor
Bionic Sight LLCIndustry
Sponsor type
Industry
First posted
Sep 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2 study, multi-center, dose-escalation interventional study of BS01 in subjects with GA secondary to dry AMD. Part 1 is an open label dose-escalation study; Part 2 is a dose-expansion study with dose(s) selected from Part 1 based on a benefit/risk assessment, and an untreated (sham injection) group to allow for a controlled comparison of efficacy and safety. This is a seamless Phase 1/2 study in up to 10 patients for Phase 1 and 30 patients Phase 2 in patients with GA secondary to dry AMD.

Conditions

  • Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)

Interventions

  • BS01Biological

    a recombinant adeno-associated virus vector expressing ChronosFP (AAV2-CAGChronosFP)

  • Sham procedure controlOther

    Sham procedure without needle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. [Phase 1] Number of the dose limiting toxicities (DLTs), incident and severity of ocular and non-ocular Study Drug-related adverse events (SDAE), treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: 12 months
  2. [Phase 2] Change from baseline in BCVA (Best Corrected Visual Acuity)Time frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • NJ Retina

    Edison, New Jersey · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.